0001209191-21-062493.txt : 20211102
0001209191-21-062493.hdr.sgml : 20211102
20211102180845
ACCESSION NUMBER: 0001209191-21-062493
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211101
FILED AS OF DATE: 20211102
DATE AS OF CHANGE: 20211102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shams Soheil
CENTRAL INDEX KEY: 0001888376
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38613
FILM NUMBER: 211372839
MAIL ADDRESS:
STREET 1: C/O BIONANO GENOMICS, INC.
STREET 2: 9540 TOWNE CENTRE DRIVE, SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bionano Genomics, Inc.
CENTRAL INDEX KEY: 0001411690
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 261756290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 888-7600
MAIL ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Bionano Genomics, Inc
DATE OF NAME CHANGE: 20190308
FORMER COMPANY:
FORMER CONFORMED NAME: BioNano Genomics, Inc
DATE OF NAME CHANGE: 20120703
FORMER COMPANY:
FORMER CONFORMED NAME: BioNanomatrix Inc
DATE OF NAME CHANGE: 20070906
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-01
0
0001411690
Bionano Genomics, Inc.
BNGO
0001888376
Shams Soheil
C/O BIONANO GENOMICS, INC.
9540 TOWNE CENTRE DRIVE, SUITE 100
SAN DIEGO
CA
92121
0
1
0
0
Chief Informatics Officer
Stock Option (Right to Buy)
5.40
2021-11-01
4
A
0
400000
0.00
A
2031-11-01
Common Stock
400000
400000
D
25% of the shares subject to the option shall vest and become exercisable on October 18, 2022, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from October 18, 2022, subject to Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan) through each such applicable vesting date and the terms of the Company's 2020 Inducement Plan.
/s/ R. Erik Holmlin, Attorney-in-Fact
2021-11-02